Cystic Fibrosis News Today Daily Digest

Cystic Fibrosis Weekly Update Contents: Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation Aug 24, 2020 07:00 am | Marisa Wexler MS The European Commission (EC) approved Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and one minimal function mutation in the CFTR gene. The decision follows a positive opinion, supporting approval, by the Committee for Medicinal Products for Human Use, a branch […] The post Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation appeared first on Cystic Fibrosis News Today. Read More Recent News NuvoAir Home Platform Classified as Class Im Medical Device EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US FDA Grants Orphan Drug Designation to KB407, Potential Gene Therapy for CF Dosing Begins in Phase 1 Trial of ETD002, Potential CF Inhalation Therapy The Painful Truth About Being a Sick Parent